Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study

Eriksson, Anna; Jonasson, Lena; Lindahl, Tomas; Hedbäck, Bo; Whiss, Per A

doi:10.1186/1479-5876-7-42

Cited by 10 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This concept has been used in cancer 146 and atherosclerosis. 74,147 In parallel, microfluidic technologies developed recently have paved the way for widespread utilization of cellular adhesion as a clinical marker due to their ease of use, short analysis time, and enhanced capacity to mimic physiological conditions. 65-67 Hydroxyurea, the only approved pharmaceutical treatment for SCD, increases HbF content in the RBCs in some, but not all, treated subjects.…”

Section: Discussionmentioning

confidence: 99%

Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease

Alapan

Kim

Adhikari

et al. 2016

Translational Research

105

View full text Add to dashboard Cite

Sickle cell disease (SCD) afflicts millions of people worldwide and is associated with considerable morbidity and mortality. Chronic and acute vaso-occlusion are the clinical hallmarks of SCD and can result in pain crisis, widespread organ damage, and early movtality. Even though the molecular underpinnings of SCD were identified more than 60 years ago, there are no molecular or biophysical markers of disease severity that are feasibly measured in the clinic. Abnormal cellular adhesion to vascular endothelium is at the root of vaso-occlusion. However, cellular adhesion is not currently evaluated clinically. Here, we present a clinically applicable microfluidic device (SCD biochip) that allows serial quantitative evaluation of red blood cell (RBC) adhesion to endothelium-associated protein-immobilized microchannels, in a closed and preprocessing-free system. With the SCD biochip, we have analyzed blood samples from more than 100 subjects and have shown associations between the measured RBC adhesion to endothelium-associated proteins (fibronectin and laminin) and individual RBC characteristics, including hemoglobin content, fetal hemoglobin concentration, plasma lactate dehydrogenase level, and reticulocyte count. The SCD biochip is a functional adhesion assay, reflecting quantitative evaluation of RBC adhesion, which could be used at baseline, during crises, relative to various long-term complications, and before and after therapeutic interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease

Alapan

Kim

Adhikari

et al. 2016

Translational Research

105

View full text Add to dashboard Cite

show abstract

“…17 Briefly, samples were diluted with EIA buffer to bring their concentrations within the range of the standard curve. No other purification was performed on any of the samples.…”

Section: Serum Thromboxane Bmentioning

confidence: 99%

Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

Capodanno

Patel

Dharmashankar

et al. 2011

Circ: Cardiovascular Interventions

179

View full text Add to dashboard Cite

Background-Patients with type 2 diabetes mellitus (T2DM) have reduced aspirin-induced pharmacodynamic effects. This may be attributed to increased platelet turnover rates resulting in an increased proportion of non-aspirin-inhibited platelets during the daily dosing interval. The hypothesis of this study was that an increase in the frequency of drug administration [twice daily (bid) versus once daily (od)] may provide more effective platelet inhibition in T2DM patients. Methods and Results-T2DM patients with stable coronary artery disease were prospectively recruited. Patients modified their aspirin regimen on a weekly basis according to the following scheme: 81 mg/od, 81 mg/bid, 162 mg/od, 162 mg/bid, and 325 mg/od. Pharmacodynamic assessments included light-transmittance aggregometry after arachidonic acid, collagen and adenosine diphosphate stimuli; VerifyNow-Aspirin assay; and serum thromboxane B 2 (TXB 2 ) levels. Twenty patients were analyzed. All patients were sensitive and compliant to aspirin irrespective of dose, as assessed by arachidonic acid-induced aggregation. When aspirin was administered once daily, there was no significant effect on platelet reactivity by increasing the once-daily dosing using aspirin-sensitive assays (collagen-induced aggregation and VerifyNow-Aspirin). An increase in aspirin dose by means of a second daily administration was associated with a significant reduction in platelet reactivity assessed by collagen-induced aggregation and VerifyNow-Aspirin between 81 mg/od and 81 mg/bid (PϽ0.05 for both assays) and between 81 mg/od and 162 mg/bid (PϽ0.05 for both assays). There was no impact of aspirin dosing regimens on adenosine diphosphate-induced aggregation. A dose-dependent effect of aspirin was observed on serum TXB 2 levels (Pϭ0.003). Conclusions-Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB 2 levels. The clinical implications of a modified aspirin regimen tailored to T2DM patients warrant further investigation. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01201785.

show abstract

“…The investigation into the etiopathogenesis and pathogenesis of AS and the development of effective measures to delay and reverse the progression of AS, thereby reducing mortality from cardiovascular and cerebrovascular diseases, has become an important field of study (8–10). However, AS has a complex, multifactorial pathophysiology and a number of risk factors work together to shape atherosclerotic plaques.…”

Section: Discussionmentioning

confidence: 99%

Fibrinogen facilitates atherosclerotic formation in Sprague-Dawley rats: A rodent model of atherosclerosis

Zhou

Pan

Zhai

2013

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Fibrinogen (Fg) contributes to thrombosis and hemostasis and plays a role in inflammation. Fg is also known to play a significant role in atherosclerosis (AS). P-selectin has been associated with AS. The present study aimed to identify the role of Fg in AS and to examine the possible mechanisms behind the effects of fibrinogen on AS using Sprague-Dawley (SD) rats as a model system. Diet-induced atherosclerotic SD rats were adopted as the experimental models. Fg was transfused into these rats and the degree of atherosclerotic lesion development was compared with that of control rats. Blood was obtained from the common abdominal aorta and then the biochemical characteristics were measured and ELISA assays performed. The aortas were then carefully separated, removed and placed in 10% (w/v) neutral formalin for use at a later stage. The root of the aorta was cut and samples were washed, dehydrated, cleared, dipped in wax, embedded, sliced, coated, grilled and stained with HE. Pathological HE-stained sections were examined by light microscopic analysis and immunohistochemistry was performed for Fg and P-selectin on representative tissue sections. The Fg-transfused, high-fat diet-fed group developed atherosclerotic lesions more readily compared with the control group. Immunohistochemical analysis revealed that Fg expression was higher in the endarterium of the Fg-transfused, high-fat diet-fed rats. P-selectin expression was also found to be correlated with Fg expression. Fg actively promotes atherosclerotic lesion development; one possible mechanism behind this is the ability of Fg to enhance P-selectin expression, which is also able to facilitate the development of atherosclerotic lesions.

show abstract

Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study

Cited by 10 publications

References 54 publications

Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease

Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease

Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

Fibrinogen facilitates atherosclerotic formation in Sprague-Dawley rats: A rodent model of atherosclerosis

Contact Info

Product

Resources

About